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Summary
Levels of factorVIII (FVIII) are associated with the risk of venous
thrombosis.The FVIII variation D1241E has been reported to be
associated with decreased levels of FVIII. Our objective was to
study whether D1241E is associated with levels of FVIII and the
risk of venous thrombosis and whether this association is
caused by D1241E or another linked variation.We analyzed the
association of three FVIII gene haplotypes encoding 1241E
(further denoted as HT1, HT3, and HT5) with FVIII levels and
thrombosis risk. This analysis was performed in the Leiden
Thrombophilia Study (LETS). The control populations of two
case-controls studies on arterial thrombosis in men and
women, respectively,were used to confirm the effects observed
on FVIII:C in the LETS. In men,HT1 was associated with a 6% re-
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duction in FVIII:C and with a reduced risk of venous thrombosis
[odds ratio 0.4 (CI95 0.2–0.8)]. Logistic regression showed that
the risk reduction was only partially dependent of the reduction
in FVIII levels. HT1 showed no effects in women on either
FVIII:C or risk of thrombosis.The number of carriers of HT3 and
HT5 was too low to make an accurate estimate of the risk of ve-
nous thrombosis. Neither HT3 nor HT5 showed effects on le-
vels of FVIII:C.When we consider that all three haplotypes en-
coding 1241E show different effects on FVIII:C and thrombosis
risk, it is possible that D1241E is not the functional variation.
However, FVIII gene variations do contribute to both levels of
FVIII and the risk of thrombosis.
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Introduction
Several studies have shown that elevated levels of coagulation
factor VIII (FVIII) are an important risk factor of venous throm-
bosis.This risk remains after adjusting for the main determinants
of FVIII levels, ABO blood group and von Willebrand factor
(VWF) (1–8). FVIII activity (FVIII:C) ≥ 150 IU/dl increases the
risk of a first venous thrombosis five-fold compared to levels
below 100 IU/dl. The frequency of FVIII:C ≥ 150 IU/dl among
thrombosis patients is 25%. Since these levels are found in 10%
of the population, the contribution of elevated FVIII levels to all
thrombotic events in the population is considerable (1).
Several lines of evidence support the idea that high FVIII le-
vels are indeed causative to thrombosis and not a consequence of
the thrombotic event, such as a dose-dependent relationship with
risk (1), persistence of elevated levels over time (4), no indi-
cations for an acute phase response (9), the induction of throm-
bosis by high FVIII in mouse models (10), dependency on ABO
blood group and the familial clustering of FVIII levels (11). The
latter, familial clustering, supports the hypothesis that FVIII le-
vels are, at least in part, determined genetically (12). So far, no
genetic variations have been found in the gene encoding FVIII
that are associated with an increase in levels and thrombotic risk
(6, 13). Recently however, a single nucleotide polymorphism
(SNP), c94901g (14), causing an amino acid change in the B-
domain of FVIII, Asp1241Glu (D1241E), has been reported to
be associated with a decrease in FVIII:C. Machiah et al. (15)
found that this polymorphism accounts for approximately 5% of
the total variation in FVIII:C in the families of the GAIT study.
More recently, Scanavini et al. (16) reported that 1241E is as-
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sociated with an 11% reduction in FVIII:C in 145 healthy
women and 150 thrombotic women. Since high FVIII:C in-
creases the risk of thrombosis, conditions associated with re-
duced FVIII:C levels are expected to be associated with a de-
crease in risk. However, Machiah et al. did not report estimations
on risk, and Scanavini et al. did not find significant differences in
genotype distribution between cases and controls (15, 16).
It is unclear through which mechanism the 1241E variant
could influence levels of FVIII. Scanavini et al. hypothesized
that the variation might be involved in APC resistance, but could
not demonstrate this (16). It is very well possible that D1241E is
not causal to the decrease in levels, but that c94901g encoding
D1241E is in linkage disequilibrium with the causal variation.
On the website of SeattleSNPs (14), SNP and haplotype data are
presented for a wide variety of genes, including the gene en-
coding FVIII. These data are based on the re-sequencing of these
genes in 23 subjects of European-American descent. In this
population the SNP c94901g encoding 1241E is present in at
least three different haplotypes of which possibly only one could
be responsible for the reported effects on FVIII levels.
To investigate the influence on FVIII:C and on the risk of ve-
nous thrombosis, we studied the effect of these three common
haplotypes encoding the 1241E variant in the Leiden Throm-
bophilia Study (LETS), a large population based case-control
study on venous thrombosis. Associations found between these
haplotypes and FVIII:C in the LETS were also evaluated in the
control subjects of two large population-based case-control
studies on arterial thrombosis, the Study of Myocardial Infarc-
tions Leiden (SMILE), consisting of men under the age of 70
years, and the Risk of Arterial Thrombosis In Relation to Oral
Contraceptives Study (RATIO), consisting of women under the
age of 50 years.
Patients and methods
Study populations
Leiden Thrombophilia Study (LETS)
The LETS consists of 474 consecutive patients and 474 controls.
All patients were referred for anticoagulant treatment after a first
objectively confirmed episode of deep vein thrombosis without
an underlying malignancy. Controls were matched for sex and
age and were acquaintances or partners of the patients. Mean age
for both patients and control subjects was 45 years, ranging from
15 to 69 years for patients and 15 to 72 years for controls. Both
groups consisted of 272 women (57.4%) and 202 men (42.6%).
All patients and controls were of Dutch origin. DNA samples
were available of 471 cases and 471 controls. FVIII:C was
measured in the plasma of all participants by a one-stage clotting
assay. Levels are expressed as IU/dl (1). VWF:Ag was measured
by ELISA in the plasma of the first 301 patients and 301 con-
trols. Levels are expressed as IU/ml (1). Pooled normal plasma,
calibrated directly against the WHO standard forVWF and FVIII
(91/666) was used as a reference. In each assay, two control plas-
mas were included for inter-assay quality assurance. Plasma
samples had not been thawed and refrozen before these measure-
ments. The design of this study has previously been described in
more detail (17).
Study of Myocardial Infarctions Leiden (SMILE)
The SMILE consists of 560 patients and 646 control subjects of
which only the controls were included here. Cases were men
below the age of 70, diagnosed with a first myocardial infarction.
The control group consisted of men who were referred to the
Leiden Anticoagulation Clinic for prophylactic anticoagulation
therapy for a short period following minor orthopaedic interven-
tions. Controls did not have a history of myocardial infarction
and had not used anticoagulants for a period of at least six
months prior to participating in this study. Controls were fre-
quency matched to cases on 10-year age groups. All patients and
controls were of Dutch origin. Plasma and DNA samples were
available of all participants. Plasma FVIII:C was measured in
two dilutions by a one-stage clotting assay with FVIII deficient
plasma and automated activated partial thromboplastin time
(APTT, Organon Teknika, Boxtel, The Netherlands) on a STA
(Diagnostic Stago, Boehringer Mannheim, Mannheim, Ger-
many). Levels are expressed as IU/dl. Pooled normal plasma,
calibrated against an in-house standard, which was calibrated
against the WHO standard for VWF and FVIII (91/666), was
used as a reference. In each assay, two control plasmas were in-
cluded for inter-assay quality assurance. Plasma samples had not
been thawed and refrozen before these measurements. Exclusion
criteria for this study were renal disease, severe (neuro-)psychi-
atric problems or a life expectancy of less than one year. The de-
sign of this study has previously been described in more detail
(18).
Risk of Arterial Thrombosis in Relation to Oral Contraceptives
Study (RATIO)
The RATIO is a case-control study with patients with different
vascular events (ischemic stroke, peripheral vascular disease and
myocardial infarction) and healthy controls, of which only the
controls were included here. The control group consisted of 925
women between the ages of 18 to 49 who had no history of cor-
onary, cerebral, or peripheral arterial disease. Controls were se-
lected via Random Digit Dialling. Only controls of which plas-
ma samples were available (639 women) were included for the
current study. Ninety-three percent of the controls were Cauca-
sian.
Plasma FVIII:C was measured in two dilutions in duplicate
by a one-stage clotting assay with FVIII deficient plasma and
automated activated partial thromboplastin time (APTT, Orga-
non Teknika) on a STA (Diagnostic Stago, Boehringer Mann-
heim). Levels are expressed as IU/dl. VWF:Ag was measured by
ELISA, using polyclonal antibodies (Dako, High Wycombe,
UK). Levels are expressed as IU/dl. Pooled normal plasma, cali-
brated against an in-house standard which was calibrated against
the WHO standard for VWF and FVIII (91/666) was used as a
reference. In each assay, two control plasmas were included for
inter-assay quality assurance. Plasma samples had not been
thawed and refrozen before these measurements. The design of
this study has previously been described in more detail (19).
Combined control populations
Because the FVIII gene is located on the X-chromosome, effects
were studied in detail in men and women separately. Combining
the different control populations, two large control groups were
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formed, all male and all female, respectively. The first control
group consisted of all male control subjects from the LETS and
all control subjects from the SMILE. The second control group
consisted of all female control subjects from the LETS and all
control subjects from the RATIO. Because controls were se-
lected stratified for age and because age is known to influence
FVIII levels, all analyses on levels were repeated after adjusting
for age using linear regression. VWF levels and blood group
were not determined in all individuals, so overall correction for
these factors was not possible. Analyses were also performed
after normalization of levels per study.
Genetic analysis
According to SeattleSNPs (April 2004), the SNP encoding the
1241E variant is present in at least three FVIII haplotypes, indi-
cated throughout this paper as HT1, HT3 and HT5. Haplotypes
are depicted in Table 1. In order to identify carriers of these ha-
plotypes, c94901g [numbering according to SeattleSNPs, April
2004 (14); rs1800291], encoding D1241E was determined in all
individuals. Subsequently, two haplotype tagging SNPs specific
for HT3 and HT5, g24052a (rs6655259) and g27882c (rs-
number pending), respectively, were determined in both hetero-
and homozygous carriers of the 1241E encoding allele. Geno-
typing was performed using either polymerase chain reaction –
restriction fragment length polymorphisms analyses (PCR-
RFLP) or 5'nuclease/Taqman assays.
The polymerase chain reactions with fluorescent allele-spe-
cific oligonucleotide probes (Assay-by-Design,Applied Biosys-
tems, Foster City, CA, USA) and for PCR-RFLP were perform-
ed on a PTC-225 thermal cycler (Biozym, Hessisch Oldendorf,
Germany). Fluorescence endpoint reading for allelic discrimi-
nation of the 5'nuclease/Taqman assay was done on an ABI 7900
HT (Applied Biosystems). PCR conditions, restriction endonu-
cleases and the sequences of probes and primers used for geno-
typing are available on request. Genotyping was successful in all
but eight samples for g24052a (three from the LETS, four from
the SMILE and one from the RATIO) and two samples for
g27882c (1 from the SMILE and 1 from the RATIO). There was
no evidence for the existence of other haplotypes than the three
proposed by SeattleSNPs.
Sequencing
All exons and exon-intron boundaries of the FVIII gene were se-
quenced in DNA samples of nine individuals. Selection criteria
for these individuals are described under „Results“.
PCR Primers for all 26 exons of the FVIII gene were de-
signed from the FVIIII reference sequence (Accession number
AH002692.1). The primers are extended either with an M13-for-
ward or with an M13-reverse sequence. All primers were de-
signed to include complete exon-intron transitions. Fragments
for exon 1 and exon 14 were split into two and 10 overlapping
fragments, respectively. PCRs were performed in a 25-µl reac-
tion volume, with a final MgCl
2
concentration of 1.5 mM except
for exon 13. All PCR programs included an initial denaturation
of 5 min by 95°C, followed by 35 cycles of 30 s at 94°C, 30 s at
either 55°C, 53°C, or 50°C and a final extension at 72°C was per-
formed for 5 min. The PCR products were sequenced in both for-
ward and reverse direction on anABI Prism 3730 DNAAnalyzer
(Applied Biosystems) using the ABI Prism BigDye Terminator
Cycle Sequencing Ready Reaction Kit (Applied Biosystems).
The raw sequence data were analyzed using SeqScape Software
for comparative sequencing analysis (Applied Biosystems). All
primers and PCR-conditions are available on request.
Statistical analyses
FVIII:C levels are presented as means with their standard devi-
ation (SD). To evaluate the difference in levels between groups
Student’s t-test was used. The differences, together with the 95%
confidence intervals (CI95) of the differences, are given. The
differences in FVIII levels between groups were also studied
after adjustment for age using linear regression. To evaluate the
influence of the different geno- and haplotypes on the risk of
thrombosis, odds ratios (OR) and their corresponding CI95 ac-
cording to Woolf (20) were calculated. ORs were corrected for
levels of FVIII using logistic regression.
Results
c94901g, encoding D1241E, was in Hardy-Weinberg equilib-
rium for the female controls of the LETS and RATIO. The haplo-
types present in the LETS, SMILE and RATIO were in accord-
ance with those reported by SeattleSNPs. Haplotype frequencies
were slightly lower than previously reported (14). They were ap-
proximately 14% for HT1 and 2% for both HT3 and HT5 in all
three studies.
FVIII haplotypes and levels of FVIII
Effects of the FVIII gene variations on levels of FVIII in controls
of the separate studies are presented in Tables 2A and B. Results
and analyses of the combined control groups are presented in
Tables 3A and B.
For D1241E in all the controls combined, lower levels of
FVIII:C were observed in the absence of the 1241D encoding al-
lele. Heterozygous carriers and homozygous wildtype carriers
had similar levels of FVIII.
In both the separate as well as the combined male control
groups, hemizygous carriers of the 1241E encoding alleles had
lower levels of FVIII (Tables 2A and 3A). In the combined con-
trol group, FVIII:C was reduced by 6%. Looking at the three sep-
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Table 1: Haplotypes on the FVIII gene. SNP numbering according
to SeattleSNPs (April 2004). SNPs indicated with „*“ are used to tag ha-
plotypes (94901 encodes D1241E). SNP 94901 distinguishes HT1, HT3
and HT5 from the all-common form and 24052 and 27882 tag HT3 and
HT5, respectively.
arate haplotypes, HT1, HT3 and HT5, the reduction disappeared
for carriers of HT3. For carriers of HT5, a reduction in FVIII:C
was observed; however, with wide confidence intervals. Also,
correction for age made the reduction much smaller while con-
fidence intervals remained wide. For HT1 however, the 6% re-
duction in FVIII:C remained (Table 3A).
In the female control groups, no clear effect of the 1241E en-
coding alleles on levels of FVIII was observed (Tables 2B and
3B).Also, the separate haplotypes showed no consistent effects.
In both the male and the female control group, VWF:Ag,
which was measured in the RATIO and in part of the LETS only,
was not influenced by either D1241E or by the three haplotypes.
In those subgroups where VWF and ABO blood group were
measured, correction forVWF and blood group did not influence
the outcomes.
FVIII haplotypes and the risk of venous thrombosis
The risk of venous thrombosis in the LETS (Table 4A)
Overall, men and women combined, 1241E appeared to slightly
decrease the risk of venous thrombosis. Homozygous carriers of
the E encoding alleles had an OR of 0.7 (CI95 0.4–1.1). When
stratified for haplotypes, it became clear that this risk reduction
was caused by HT1. Homozygous carriers of HT1 had an OR of
0.5 (CI95 0.3–0.9). For HT3 and HT5 no reduction in risk was
observed.
The risk of venous thrombosis in men (Table 4B)
In men alone we found a more pronounced protective effect of
the 1241E encoding alleles against venous thrombosis. Carriers
of 1241E had an OR of 0.5 (CI95 0.3–0.9). After stratification
for haplotypes this reduction in risk remained mainly for HT1. It
was even more pronounced for carriers of HT1 for which the OR
was 0.4 (CI95 0.2–0.8).
Male
controls
Geno- /
haplotype (N)
LETS SMILE
N Mean FVIII:C (SD) N Mean FVIII:C (SD)
D1241E D (701) 163 110.6 (28.8) 538 124.3 (33.2)
- E (145) 38 101.9 (31.6) 107 119.2 (35.6)
HT1 HTx (726) 170 110.2 (29.4) 556 124.2 (33.1)
- HT1 (118) 30 102.5 (29.8) 88 119.2 (36.4)
HT3 HTx (829) 196 109.1 (29.1) 633 123.5 (33.6)
- HT3 (15) 4 109.0 (50.4) 11 125.8 (33.4)
HT5 HTx (835) 198 109.2 (29.3) 637 123.6 (33.6)
- HT5 (10) 3 90.7 (36.5) 7 114.9 (30.2)
A)
Female
controls
Geno- /
haplotype (N)
LETS RATIO
N Mean FVIII:C (SD) N Mean FVIII:C (SD)
D1241E D / D
(619)
184 111.0 (28.2) 435 114.5 (47.3)
- D / E
(245)
77 114.4 (33.5) 168 108.6 (39.9)
- E / E
(31)
9 117.4 (32.1) 22 125.4 (56.0)
HT1 HTx / HTx (673) 197 111.4 (28.7) 476 114.1 (46.2)
- HTx / HT1 (197) 67 113.8 (33.0) 130 108.4 (41.7)
- HT1 / HT1
(24)
6 118.5 (35.4) 18 127.6 (61.4)
HT3 HTx / HTx (865) 266 112.2 (29.8) 599 113.4 (46.3)
- HTx / HT3
(29)
4 106.9 (39.1) 25 111.3 (32.1)
HT5 HTx / HTx (862) 258 111.8 (29.7) 604 113.5 (46.2)
- HTx / HT5
(32)
12 120.7 (32.7) 20 109.5 (32.2)
B)
Table 2: A) FVIII:C (IU/dl) in male control subjects from the
LETS and SMILE separately. B) FVIII:C (IU/dl) in female con-
trol subjects from the LETS and RATIO separately.
Male controls Geno- /
haplotype (N)
Mean FVIII:C (SD) Δ
(CI95)
Δ*
(CI95)
D1241E D (701) 121.1 (32.7) - -
- E (145) 114.7 (35.3) 6.4
(0.4 to 12.3)
6.0
(0.2 to 11.7)
HT1 HTx (726) 120.9 (32.8) - -
- HT1 (118) 115.0 (35.5) 5.9
(-0.5 to 12.4)
6.3
(0.1 to 12.5)
HT3 HTx (829) 120.1 (33.2) - -
- HT3 (15) 121.3 (37.4) –1.3
(-18.3 to 15.7)
–2.6
(-19.0 to 13.8)
HT5 HTx (835) 120.2 (33.2) - -
- HT5 (10) 107.6 (32.3) 12.6
(-8.2 to 33.3)
5.3
(-14.7 to 25.4)
A)
Female controls Geno- /
haplotype (N)
Mean FVIII:C (SD) Δ
(CI95)
Δ*
(CI95)
D1241E D / D
(619)
113.5 (42.5) - -
- D / E
(245)
110.4 (38.0) 3.1
(-3.0 to 9.2)
3.4
(-3.4 to 10.1)
- E / E
(31)
123.1 (49.9) –9.6
(-25.1 to 5.9)
–11.2
(-28.4 to 5.9)
HT1 HTx / HTx (673) 113.3 (41.8) - -
- HTx / HT1 (197) 110.2 (39.0) 3.1
(-3.5 to 9.6)
3.3
(-4.0 to 10.6)
- HT1 / HT1
(24)
125.3 (55.5) –12.0
(-29.2 to 5.3)
–14.5
(-33.6 to 4.7)
HT3 HTx / HTx (865) 113.1 (41.9) - -
- HTx / HT3
(29)
110.7 (32.4) 2.4
(-13.1 to 17.8)
3.0
(-14.2 to 20.1)
HT5 HTx / HTx (862) 113.0 (42.0) - -
- HTx / HT5
(32)
113.7 (32.3) –0.7
(-15.4 to 14.0)
–0.3
(-16.6 to 16.1)
B)
Table 3: A) FVIII:C (IU/dl) in all male control subjects from the
LETS and SMILE. Δ is the difference between the means given with
the corresponding CI95. Δ* is the difference between the mean dis-
tances to the regression line after linear regression adjusting for age.
HTx signifies all haplotypes but the one given. B) FVIII:C (IU/dl) in all
female control subjects from the LETS and RATIO. Δ is the dif-
ference between the means given with the corresponding CI95 calcu-
lated vs. the wildtype (D / D or HTx / HTx). Δ* is the difference be-
tween the mean distances to the regression line after linear regression
adjusting for age. HTx signifies all haplotypes but the one given.
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After adjustment for FVIII:C with logistic regression, the OR
for HT1 in men was 0.5 (CI95 0.2–1.0). The reduction in FVIII
levels accounted for part of the reduction of the risk of venous
thrombosis, but HT1 seems to influence risk in a manner inde-
pendent of levels as well. HT3 and HT5 were too rare to allow
meaningful risk estimates.
The risk of venous thrombosis in women (Table 4C)
In women, virtually no effect on the risk of venous thrombosis
was observed. For both hetero- and homozygous carriers of
1241E, the OR was approximately 1. Similar ORs were observ-
ed for heterozygous carriers of HT1 and HT5 and homozygous
carriers of HT1. In heterozygous carriers of HT3, the risk ap-
peared increased (OR 2.3); however, the confidence interval was
wide (0.7–7.6).
Sequencing of the FVIII gene
The effects observed on levels of FVIII and the risk of thrombo-
sis appeared to depend mainly on HT1. To identify haplotype-
specific variations that may explain this effect, all exons and
exon-intron boundaries of the FVIII gene were sequenced in nine
male individuals, three per haplotype. Individuals were selected
on phenotype for HT1. Three male controls from the LETS,
hemizygous for HT1, were chosen with FVIII:C < 100 IU/dl be-
cause of the protective effect on venous thrombosis in men and
the reduction in FVIII:C associated with HT1. HT3 and HT5 ap-
peared not to be associated with any particular phenotype.
Therefore, for both HT3 and HT5 three hemizygous male car-
riers were selected without reference to FVIII levels.
Besides the SNPs already reported by SeattleSNPs, no haplo-
type-specific variations were found. Since none of these pre-
viously reported variations are likely to influence either protein
levels or protein function, it is possible that functional variations
lie in intronic regions of the FVIII gene.
Discussion
Elevated levels of FVIII are an important risk factor for venous
thrombosis. There are strong indications that FVIII levels are, at
least in part, determined genetically, beyond the well-known ef-
fect of ABO blood group. To assess whether the D1241E vari-
ation in the B-domain of FVIII, which in previous studies was
linked to FVIII levels, is indeed causative to the previously re-
ported effects on FVIII:C (15, 16), we genotyped two additional
SNPs to tag three haplotypes that all carry the minor allele of this
variation.
We studied these three haplotypes separately in the LETS and
in the control populations of the SMILE and the RATIO studies.
In general, FVIII:C was relatively high in all three studies. It was
shown previously in the LETS that this is not a result of acti-
vation (6) since FVIII:C were strongly associated with the actual
protein concentration (FVIII:Ag). Nor were these high FVIII le-
vels the result of an acute phase response (9). The high mean
FVIII levels were not the result of a shift in the distribution of
ABO blood groups (LETS control group, 42.6% with blood
group O). So there is no explanation for the overall slightly elev-
ated FVIII levels in our study populations. However, this elev-
ation does not affect analyses comparing effects of the different
geno- and haplotypes within these populations.
We observed an association between 1241E and lower
FVIII:C, but in men only. In men, a reduction of approximately
6% in FVIII:C was observed in those individuals with 1241E.
After stratifying for haplotypes, this effect appeared to be re-
stricted to HT1. The data also imply a reductive trend of FVIII:C
for HT5, which is genetically very similar to HT1. However if
LETS Geno- / haplotype
†
Cases Controls OR
(CI95)
D1241E D / D 363 347 1*
- D / E 75 77 0.9 (0.7 to 1.3)
- E / E 33 47 0.7 (0.4 to 1.1)
HT1 HTx / HTx 386 367 1*
- HTx / HT1 65 67 0.9 (0.6 to 1.3)
- HT1 / HT1 20 36 0.5 (0.3 to 0.9)
HT3 HTx / HTx 460 462 1*
- HTx / HT3 9 4 2.3 (0.7 to 7.4)
- HT3 / HT3 2 4 0.5 (0.1 to 2.8)
HT5 HTx / HTx 454 456 1*
- HTx / HT5 11 12 0.9 (0.4 to 2.1)
- HT5 / HT5 6 3 2.0 (0.5 to 8.1)
A)
LETS men Geno- / haplotype Cases Controls OR
(CI95)
D1241E D 180 163 1*
- E 22 38 0.5 (0.3 to 0.9)
HT1 HTx 188 170 1*
- HT1 14 30 0.4 (0.2 to 0.8)
HT3 HTx 200 196 1*
- HT3 2 4 0.5 (0.1 to 2.7)
HT5 HTx 196 198 1*
- HT5 6 3 2.0 (0.5 to 8.2)
B)
LETS women Geno- / haplotype Cases Controls OR
(CI95)
D1241E D / D 183 184 1*
- D / E 75 77 1.0 (0.7 to 1.4)
- E / E 11 9 1.2 (0.5 to 3.0)
HT1 HTx / HTx 198 197 1*
- HTx / HT1 65 67 1.0 (0.7 to 1.4)
- HT1 / HT1 6 6 1.0 (0.3 to 3.1)
HT3 HTx / HTx 260 266 1*
- HTx / HT3 9 4 2.3 (0.7 to 7.6)
HT5 HTx / HTx 258 258 1*
- HTx HT5 11 12 0.9 (0.4 to 2.1)
C)
Table 4: A) Distribution of FVIII geno- and haplotypes in all pa-
tients with venous thrombosis and controls from the LETS.
†
the homozygous genotypes also include hemizygotes. * reference
group. B) Distribution of FVIII genotypes and haplotypes in all
male patients with venous thrombosis and all male controls
from the LETS. * reference group. C) Distribution of FVIII geno-
and haplotypes in all female patients with venous thrombosis
and all female controls from the LETS. * reference group.
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HT1 and HT5 are looked at as one haplotype, the effects are
weaker then for HT1 alone.
In contrast to Scanavini et al. (16), who described an 11% re-
duction in FVIII:C in female carriers of the 1241E encoding al-
leles, we found no effects in female control subjects. Stratifying
for haplotypes made no difference. There are few differences be-
tween the female controls from the LETS and the RATIO and the
controls used by Scanavini et al. (16) that could explain these
contrasting results. Scanavini et al. (16) excluded users of oral
contraceptives, whereas we did not. However, exclusion or inclu-
sion of oral contraceptive users is highly unlikely to have in-
fluenced the results of D1241E in either study. Since prescription
of oral contraceptives does not depend on genotype, there is no
reason to assume that oral contraceptives users will be unequally
distributed over the different geno- and haplotypes.
In summary, we showed that in our study populations a re-
duction in FVIII:C is restricted to male carriers of HT1, indicat-
ing that there is another variation on this haplotype that in-
fluences FVIII:C in men only. There is no satisfactory expla-
nation for the discrepancy in effects between the two sexes.
As expected, we observed decreases in risk of venous throm-
bosis in the group where FVIII levels were decreased. In male
carriers of 1241E and particularly carriers of HT1, who showed
a 6% reduction in FVIII:C, a strong protection against venous
thrombosis was observed. It is tempting to hypothesize that this
reduction in risk is caused solely by the reduction in FVIII levels;
however, logistic regression showed that only a small part of this
effect is caused by the reduction in FVIII:C. Nonetheless, simi-
lar to the role of ABO blood group, this again is an indication for
a causative association between FVIII:C and the risk of venous
thrombosis. Besides the small effect HT1 has on the risk of ve-
nous thrombosis via a reduction in FVIII:C, adjustment with log-
istic regression showed us that HT1 influences the risk of venous
thrombosis in a manner independent of FVIII levels as well.
The data presented here suggest that the effects associated
with D1241E are limited to HT1. Thus, D1241E is not likely to
be the functional variation responsible for the effect on FVIII le-
vels and thrombosis risk as it is present in all three haplotypes.
Indeed, so far, no mechanisms for the functionality of D1241E
have been identified. The B-domain of the FVIII molecule, in
which D1241E is located, is not necessary for procoagulant ac-
tivity (21) but probably plays an important role in determining
levels of FVIII in the circulation (22). The B-domain is heavily
glycosylated. At least 19 of the 25 N-linked glycosylation sites
on FVIII are located in the B-domain (23, 24). It has been shown
that these sites play an important role in the secretion of FVIII
(25) and that they may also influence FVIII clearance from the
circulation (26). The nearest N-linked glycosylation site to
D1241E, however, is 14 residues away. Although it cannot be ex-
cluded, the minor change in the side group from aspartic acid to
glutamic acid makes it highly unlikely that D1241E would in-
fluence glycosylation in the B-domain.
After re-sequencing of the FVIII gene, we did not identify
other possibly functional variations specific for HT1. However,
we only sequenced exons and exon-intron boundaries, so addi-
tional variations undoubtedly exist within non-coding regions.
So even though no functional variant was found in HT1, and
numbers of carriers of the other two haplotypes, HT3 and HT5,
remained very small, we should seriously consider the possibil-
ity of the existence of an as yet unidentified functional mutation
in HT1 other than D1241E. At the same time, the possibility also
exists that as yet unidentified variations in HT3 and HT5 exist
that counteract the effects of D1241E, masking its functionality
in these two haplotypes.
In conclusion, we observed a reduction in FVIII:C that was
restricted to male carriers of HT1. HT1 was also associated with
a decrease in risk of venous thrombosis. A small part of this de-
crease in risk could be explained by the reduction in FVIII levels.
In addition, HT1 had a protective effect against venous thrombo-
sis, which could not be explained by the reduction in FVIII:C as
well. Although this should be investigated further, it is possible
that D1241E is not the main player in these effects, since both
carriers of HT3 and HT5 apparently show no reduction in either
FVIII:C or in the risk of venous thrombosis.
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